

Docket No. 296846US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Haruo SUGIYAMA

SERIAL NO: 10/594,507

GAU:

FILED: September 28, 2006

EXAMINER:

FOR: CANCER ANTIGEN PEPTIDES DERIVED FROM WT1

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



\_\_\_\_\_  
Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 296846US0PCT		SERIAL NO. 10/594,507	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Haruo SUGIYAMA						
		FILING DATE September 28, 2006			GROUP			
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA	7 030 212	04-18-06	SUGIYAMA, et al.				
	AB							
	AC							
	AD							
	AE							
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
	AF	2002 525099	08-13-02	JP (equivalent of US 2003 0039635 and WO 00 18795)	YES	NO		
	AG	00 26249	05-11-00	WO			NO	
	AH							
	AI							
	AJ							
	AK							
	AL							
	AM							
	AN							
	AO							
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>								
	AP	ZINSZNER, H. et al., "Nucleotide Sequence of the HLA-A26 Class I Gene: Identification of Specific Residues and Molecular Mapping of Public HLA Class I Epitopes" Human Immunology, Vol. 27, pgs. 155-166, 1990.						
	AQ	BELLANTUONO, I. et al., "Two Distinct HLA-A0201-Presented Epitopes of the Wilms Tumor Antigen 1 Can Function as Targets for Leukemia-Reactive CTL" Blood, Vol. 100, No. 10, pgs. 3835-3837, 2002.						
	AR	LIQUAN, G. et al., Selective Elimination of Leukemic CD34 <sup>+</sup> Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1, Blood, Vol. 95, No. 7, pgs. 2198-2203, 2000.						
	AS	"Funakoshi News", Frontiers in Life Science, No. 2004 Nen 3 Gatsu 1 Nichi, pgs. 1-13, 2004. (With English Translation)						
	AT	DAL PORTO, J. et al., "A Soluble Divalent Class I Major Histocompatibility Complex Molecule Inhibits Alloreactive T Cells at Nanomolar Concentrations", Proc. Natl. Acad. Sci. USA, Vol. 90, pgs. 6671-6675, 1993.						
	AU	CALL, K.M. et al., "Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus", Cell Press, Vol. 60, pgs. 509-520, 1990.						
	AV	GESSLER, M. et al., "Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome Jumping", Letters to Nature, Vol. 343, pgs. 774-778, 1990.						
	AW	MENKE, A. L. et al., "The Wilms' Tumor 1 Gene: Oncogene or Tumor Suppressor Gene?" International Review of Cytology, Vol. 181, pgs. 151-212, 1998.						
	AX	SUGIYAMA, H., "Cancer Immunotherapy Targeting WT1 Protein", International Journal of Hematology, Vol. 76, pgs. 127-132, 2002.						
	AY							
	AZ				<input type="checkbox"/> Additional References sheet(s) attached			
Examiner					Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

U.S. PCT Application Serial No: 10/594,507  
Filed: September 28, 2006  
Haruo SUGIYAMA  
Docket No. 296846US0PCT

#### STATEMENT OF RELEVANCY

- 1) References AF and AP - AT have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References [REDACTED] have been cited in the corresponding [REDACTED] Search Report. A copy of these references is being submitted herewith.
- 3) References AA, AG and AU-AX are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References [REDACTED] are additional prior art known to Applicant. A copy of these references is being submitted herewith.